Aaron Sverdlov, Co-Director of the Newcastle Centre of Excellence in Cardio-Oncology at Hunter Medical Research Institute (HMRI), shared a post on LinkedIn:
“Pleased to have presented at AstraZeneca BLAZE26 meeting yesterday on Managing Cardiovascular Risk in Blood Cancers.
- Cardiovascular care should help patients receive and remain on the best possible cancer therapy safely and not create unnecessary barriers to treatment.
- As blood cancer therapies become more effective and patients live longer, cardiovascular risk is increasingly relevant across the treatment journey, including BTK inhibitors, proteasome inhibitors, AL amyloidosis, CAR-T/bispecific therapies, HSCT and survivorship care.
The goal of cardio-oncology is to prevent, detect and manage cardiovascular complications early so we can improve outcomes and support optimal haematological treatment.
It was great to catch up with colleagues from all over Australia.”
Other articles featuring Aaron Sverdlov on OncoDaily.
